Creating Drugs at the Speed of AI: Absci

Nasdaq Listings Host, Kristina Ayanian, sits down with CEO of Absci (NSDQ: ABSI), Sean McClain, to discuss how the company is using artificial intelligence to power synthetic biology, and unlocking the potential of proteins as the next generation of therapeutics.